期刊文献+

局部晚期非小细胞肺癌β_Ⅲ-tubulin和Stathmin的表达及与紫杉醇耐药性关系的研究 被引量:1

Relationship between expression of β_Ⅲ-tubulin,stathmin and drug resistance to paclitaxel in local advanced non-small cell lung cancer
下载PDF
导出
摘要 目的:探讨局部晚期非小细胞肺癌(NSCLC)βⅢ-tubulin和Stathmin表达与紫杉醇化疗耐药性关系。方法:回顾性分析84例接受紫杉醇化疗的局部晚期NSCLC患者的临床病理资料。免疫组织化学法检测肿瘤标本βⅢ-tubulin和Stath-min蛋白的表达,并对疗效进行分析。结果:βⅢ-tubulin阳性表达率为48.81%(41/84),Stathmin阳性表达率为51.19%(43/84),均与性别、年龄及组织类型无关。化疗有效率(CR+PR)为41.67%,βⅢ-tubulin高表达的患者有效率低(24.39%),进展率高(13.89%);βⅢ-tubulin低表达患者有效率高(58.14%),进展率低(0),差异均有显著性(P<0.01)。Stathmin(+)组的有效率为27.91%,低于Stathmin(-)组的56.10%,而其进展率为11.63%,高于Stathmin(-)组0,差异均有显著性(P<0.05)。联合检测显示:βⅢ-tubulin(+)且Stathmin(+)组有效率为21.88%,βⅢ-tubulin(-)且Stathmin(-)组有效率为62.50%,两者差异显著(P<0.01)。结论:βⅢ-tubulin和Stathmin高表达的局部晚期NSCLC患者对紫杉醇化疗耐药。 Objective:To investigate the expression of βⅢ-tubulin,stathmin protein and chemoresistance to paclitaxel in locally advanced non-small cell lung cancer(NSCLC).Methods:Eighty-four patients of locally advanced NSCLC treated with paclitaxel were enrolled in this study and their tumor samples were collected retrospectively for analysis.The expression of βⅢ-tubulin,stathmin protein in tumor samples was detected by the immunohistochemical methods.The data of therapeutical effect were collected and analyzed.Results:The βⅢ-tubulin positive staining(≥50% of stained cells) accounted for 48.81%(41/84).The stathmin positive staining(≥50% of stained cells) accounted for 51.19%(43/84).There was no correlation between βⅢ-tubulin,stathmin positive expression and age,gender,pathological type.The response rate(CR+PR) was 41.67%.Patients with overexpression βⅢ-tubulin were less response rate(24.39% vs.58.14%) and more progression rate(13.89% vs.0) to paclitaxel(P〈0.01).Patients with overexpression stathmin were less response rate(27.91% vs.56.10%) and more progression rate(11.63% vs.0) to paclitaxel(P〈0.05).Patients with overexpression βⅢ-tubulin and stathmin were also lower response rate(21.88% vs.62.50%,P〈0.01).Conclusion:Overexpression of βⅢ-tubulin,stathmin in tumor cells was associated with resistance to paclitaxel in patients with local advanced NSCLC receiving paclitaxel-based chemotherapy.
出处 《临床肿瘤学杂志》 CAS 2009年第10期884-889,共6页 Chinese Clinical Oncology
基金 河北省科技计划支撑项目(072761486)
关键词 非小细胞肺癌 化学治疗 紫杉醇 微管蛋白 STATHMIN Non-small cell lung cancer Chemotherapy Paclitaxel Tubulin Stathmin
  • 相关文献

参考文献14

  • 1Seve P,Mackey J,Isaac S,et al.Class Ⅲ beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel[J].Mol Cancer Ther,2005,4(12):2001-2007. 被引量:1
  • 2Alli E,Bash-Babula J,Yang JM,et al.Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer[J].Cancer Res,2002,62(23):6864-6869. 被引量:1
  • 3Seve P,Isaac S,Tredan O,et al.Expression of class Ⅲ {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy[J].Clin Cancer Res,2005,11(15):5481-5486. 被引量:1
  • 4Chen G,Wang H,Gharib TG,et al.Overexpression of oncoprotein 18 correlates with poor differentiation in lung adenocarcinomas[J].Mol Cell Proteomics,2003,2(2):107-116. 被引量:1
  • 5Monzo M,Rosell R,Sanchez JJ,et al.Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations[J].J Clin Oncol,1999,17(6):1786-1793. 被引量:1
  • 6Kelley MJ,Li S,Harpole DH.Genetic analysis of the beta-tubulin gene,TUBB,in non-small-cell lung cancer[J].J Natl Cancer Inst,2001,93(24):1886-1888. 被引量:1
  • 7Kavallaris M,Burkhart CA,Horwitz SB.Antisense oligonucleotides to class Ⅲ beta-tubulin sensitize drug-resistant cells to Taxol[J].Br J Cancer,1999,80(7):1020-1025. 被引量:1
  • 8Mozzetti S,Ferlini C,Concolino P,et al.Class Ⅲ beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients[J].Clin Cancer Res,2005,11(1):298-305. 被引量:1
  • 9Rosell R,Scagliotti G,Danenberg KD,et al.Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer[J].Oncogene,2003,22(23):3548-3553. 被引量:1
  • 10Paradiso A,Mangia A,Chiriatti A,et al.Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer[J].Ann Oncol,2005,16(Suppl 4):14-19. 被引量:1

同被引文献18

  • 1Paul E.VAN SCHIL Michèle DE WAELE Jeroen M.HENDRIKS Patrick R.LAUWERS.Is there a role for surgery in stage ⅢA-N2 non-small cell lung cancer?[J].中国肺癌杂志,2008,11(5):615-621. 被引量:14
  • 2Ikeda S, Takabe K, Suzuki K. Expression of ERCC1 and class Ⅲβ tubulin for predicting effect of Caboplatin/Paclitaxel in patients with advanced inoperable non-small cell lung cancer [ J ]. Pathol Int, 2009,59 (12) : 863-867. 被引量:1
  • 3Hayashi Y, Kuriyama H, Umezu H, et al. Class Ⅲ betatubulin expression in tumor cells is correlated with resistance to Docetaxel in patients with completely reseeted non-small-cell lung cancer [J]. Inter Med, 2009,48(4):203-208. 被引量:1
  • 4Seve P, Lai R, Ding K, et al. Class Ⅲ beta-tubulin expression and benefit from adjuvant Cisplatin/Vinorelbine chemotherapy in operable non-small cell lung cancer: Analysis of NCIC JBR. 10 [J]. Clin Cancer Res, 2007,13(3) :994-999. 被引量:1
  • 5Koh Y, Jang B, Han SW, et al. Expression of class Ⅲ beta- tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer [J].J Thorac Oncol, 2010,5 (3) : 320-325. 被引量:1
  • 6Kamath K, Wilson L, Cabral F, et al. beta Ⅲ-tubulin induces Paclitaxel resistance in association with reduced effects on microtubule dynamic instability [J]. J Biol Chem, 2005,280 (13) : 12902-12907. 被引量:1
  • 7Hari M, Yang H, Zeng C, et al. Expression of class Ⅲ betatubulin reduces microtubule assembly and confers resistance to Paclitaxel [J ]. Cell Motil Cytoskeleton, 2003,56( 1 ):45-56. 被引量:1
  • 8Kavallaris M, Tait AS, Walsh B J, et al. Multiple microtubule alterations are associated with vinca alkaloid resistance in human leukemia cells [J ]. Cancer Res, 2001,61 (15) :5803- 5809. 被引量:1
  • 9Seve P, Reiman T, Dumontet C. The role of βⅢ tubulin in predicting chemoresistance in non-small cell lung cancer [J]. Lung Cancer, 2010,67(2) : 136-143. 被引量:1
  • 10Kavallaris M, Burkhart CA, Horwitz SB. Antisense oligonueleotides to class Ⅲ beta-tubulin sensitize drug-resistant cells to Taxol [J]. Br J Cancer, 1999,80(7) : 1020-1025. 被引量:1

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部